{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:37:42Z","timestamp":1758040662556,"version":"3.44.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.amjmed.2005.06.002","type":"journal-article","created":{"date-parts":[[2005,11,5]],"date-time":"2005-11-05T07:37:45Z","timestamp":1131176265000},"page":"1183-1189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A rational approach to evidence gaps in the management of osteoporosis"],"prefix":"10.1016","volume":"118","author":[{"given":"Clifford J.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.06.002_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.06.002_bib2","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI113523","article-title":"Age and bone mass as predictors of fracture in a prospective study","volume":"81","author":"Hui","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2005.06.002_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF00310197","article-title":"Predicting various fragility fractures in women by forearm bone densitometry","volume":"52","author":"Gardsell","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.amjmed.2005.06.002_bib4","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","article-title":"Identification of fracture outcomes of undiagnosed low bone mineral density in postmenopausal women","volume":"286","author":"Siris","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.06.002_bib5","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/JBMR.040508","article-title":"Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older","volume":"19","author":"Siris","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib6","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1359\/jbmr.2002.17.12.2222","article-title":"Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry","volume":"17","author":"Miller","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1359\/JBMR.041216","article-title":"Absolute versus relative fracture risk","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1359\/JBMR.041215","article-title":"Absolute versus relative fracture risk","volume":"20","author":"Johnston","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.06.002_bib10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.06.002_bib11","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.06.002_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2005.06.002_bib14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis:the prevent recurrence of osteoporotic fractures study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.06.002_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4065\/80.3.343","article-title":"Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of \u22121.6 to \u22122.5 at the femoral neck","volume":"80","author":"Quandt","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjmed.2005.06.002_bib19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","article-title":"Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial","volume":"131","author":"Ravn","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Ostoeporosis Prevention Study Group","volume":"128","author":"McClung","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib22","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib23","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density","volume":"276","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.06.002_bib24","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.291.16.1999","article-title":"Effect of vitamin D on falls","volume":"291","author":"Bischoff-Ferrari","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.06.002_bib25","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1067\/mob.2001.117669","article-title":"Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmeopausal women","volume":"185","author":"Gambacciani","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.amjmed.2005.06.002_bib26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experiences with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib27","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2005.06.002_bib29","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.amjmed.2005.06.002_bib30","first-page":"S45","article-title":"A 5 year randomized trial of the long-term efficacy and safety of alendronate","volume":"19","author":"Black","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","article-title":"Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles","volume":"28","author":"Mashiba","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2005.06.002_bib32","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1172\/JCI116872","article-title":"The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates","volume":"92","author":"Balena","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2005.06.002_bib33","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1359\/JBMR.040126","article-title":"Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib","volume":"19","author":"Komatsubara","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib34","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2005.06.002_bib35","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2005.06.002_bib36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.amjmed.2005.06.002_bib37","first-page":"961","article-title":"Comparative study of alendronate versus etidronate for the treatment of Paget\u2019s disease of bone","volume":"81","author":"Siris","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib38","first-page":"S45","article-title":"Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women","volume":"19","author":"Recker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib39","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib40","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2005-0057","article-title":"Long-term safety of bisphosphonates","volume":"90","author":"Ott","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.amjmed.2005.06.002_bib42","first-page":"190","article-title":"Author\u2019s reply","volume":"351","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(03)00112-1","article-title":"Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal","volume":"33","author":"Bagger","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2005.06.002_bib44","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1185\/030079904125004475","article-title":"Bone safety of long-term bisphosphonate treatment","volume":"20","author":"Rodan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjmed.2005.06.002_bib45","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment with postmenopausal osteoporosis","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib46","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.amjmed.2005.06.002_bib47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.GME.0000086467.82759.DA","article-title":"Recency and duration of postmenopausal hormone therapy","volume":"10","author":"Barrett-Connor","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.amjmed.2005.06.002_bib48","first-page":"720","article-title":"Alendronate and estrogen effects in postmenopausal women with low bone mineral density","volume":"85","author":"Bone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib49","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/humrep\/15.10.2087","article-title":"Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis","volume":"15","author":"Tiras","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.amjmed.2005.06.002_bib50","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/jcem.87.4.8323","article-title":"Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis","volume":"87","author":"Palomba","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib51","first-page":"3076","article-title":"Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis","volume":"84","author":"Lindsay","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib52","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1210\/jc.2003-030198","article-title":"Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis","volume":"89","author":"Evio","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib53","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0015-0282(03)00757-X","article-title":"Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women","volume":"80","author":"Davas","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.amjmed.2005.06.002_bib54","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","article-title":"Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women","volume":"289","author":"Greenspan","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.06.002_bib55","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib56","first-page":"1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"86","author":"Harris","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib57","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy","volume":"16","author":"Cosman","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib58","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.06.002_bib59","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","article-title":"Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women","volume":"13","author":"Cosman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib60","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib61","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib62","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1210\/en.2002-221061","article-title":"New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats","volume":"144","author":"Ma","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.amjmed.2005.06.002_bib63","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjmed.2005.06.002_bib64","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2005.06.002_bib65","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"The effect of 1 year of alendronate following 1 year of PTH 1-84","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.06.002_bib66","first-page":"620","article-title":"A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporsosis","volume":"82","author":"Hodsman","year":"1997","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305004316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305004316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:38:58Z","timestamp":1757579938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305004316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0002934305004316"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.06.002","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2005,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rational approach to evidence gaps in the management of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}